Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 26, 2015

View Archived Issues

Studies support switching to infliximab biosimilar for Crohn's disease and ulcerative colitis

Ferring Pharmaceuticals acquires drug delivery technology from CTCBIO

PaQ device improves glycemia control in patients with diabetes

InSys in-licenses novel therapy for chronic pelvic pain syndrome

CymaBay reports phase IIb results for arhalofenate in gout

Pfizer releases results from phase II trial of Trumenba administered with other vaccines in children

Endpoints met in Teva's phase IIb study of TEV-48125 for prevention of chronic migraine

Novel TNKS1/2 inhibitor shows potential for in vivo inhibition of Wnt pathway

Phase III SUMMIT-07 study of NKTR-181 begins in patients with chronic low back pain

MicuRx begins U.S. phase II trial of MRX-I

Bristol-Myers Squibb to acquire Flexus Biosciences

Favipiravir evaluated in phase II Ebola virus disease trial

N30 Pharmaceuticals changes name to Nivalis Therapeutics

First launch of Takecab in Japan

Regen BioPharma updates development progress of dCellVax

FDA approves Avycaz for cIAI and cUTI

Fujian Haixi Pharmaceuticals patent reports development of BTK inhibitors

Takeda describes FFA1 receptor agonists for diabetes

Roche patents compounds for treatment of RSV

Wee1-like protein kinase inhibitors prepared and tested at Almac Discovery

Merck & Co. synthesizes new orexin OX2 receptor antagonists

NICE issues final guidance on biologic therapies for ulcerative colitis

Medicago awarded Ebola antibody contract by BARDA

Shionogi starts phase III trial of peptide vaccine S-588410 for esophageal cancer

EMA awards orphan drug designation to alvocidib for AML

NGM and Merck & Co. to discover, develop and commercialize novel biologic therapeutics

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 16, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 16, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Hits’ Hyperlab launches as ‘virtual AI lab’ for new drug discovery
BioWorld Science
Things once done in laboratories can now be done with computers and AI, said Kim Woo-youn, CEO and cofounder of Hits Inc. “We live in the age of ‘digital...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...